We rely on peer-reviewed scientific research to determine what’s truly effective. Our goal is to provide clear, unbiased information to help you make better health decisions.
We use AI tools to help summarize studies, and every piece of content is reviewed and approved by qualified experts, ensuring it’s accurate and trustworthy.
Beta Glucan is fully independent — we don’t sell products, run ads, or accept sponsorships. Our only focus is delivering reliable, science-backed insights.
Key study details
Objective
Evaluate immune and metabolic effects of two orally administered β-1,3/1,6-glucans produced by novel Aureobasidium pullulans strains (AFO-202; N-163) in healthy middle-aged men and explore whether a single-strain vs combined-strain regimen differentially modulates glycemic, lipid and inflammatory/immune markers.
Methods
- Exploratory, randomized, controlled pilot in 16 healthy Japanese males (40–60 y) divided into four groups (n=4 each):
- Group I: AFO-202 β-glucan 2×1 g sachets/day; sub-groups IA (35 days) and IB (21 days).
- Group II: AFO-202 2×1 g/day + N-163 β-glucan (15 g gel/day); sub-groups IIA (35 days) and IIB (21 days).
- Pre-/post-treatment comparisons assessed: HbA1c, glycated albumin (GA), LDL-C/total, CRP, D-dimer, differential leukocytes, NLR, and composite ratios LCR and LeCR; additional markers included CD11b, ferritin, galectin-3, fibrinogen.
- A day-21 vs day-35 comparison was conducted.
Results
- Glycaemia: HbA1c and GA decreased within Group I (AFO-202 alone).
- Lipids: Total-C and LDL-C decreased within Group II (AFO-202+N-163).
- Inflammation/immunity:
- In Group I, eosinophils/monocytes increased, D-dimer and NLR decreased, while LCR/LeCR increased.
- In Group II, CD11b, ferritin, galectin-3, and fibrinogen decreased.
- Duration effect: No statistically significant differences between day 21 and day 35 across groups.
Our take
Interpretation
Short-term A. pullulans β-glucans showed improvements: AFO-202 alone favored glycemic and selected immuno-inflammatory shifts, whereas the AFO-202+N-163 combination favored lipid lowering and reductions in innate-activation/iron-storage/fibrogenic markers (CD11b, ferritin, galectin-3, fibrinogen). Between-group statistical comparisons are not detailed; findings should be viewed as signal-generating rather than confirmatory.
Mechanisms and pathways
The study infers immunomodulation from changes in leukocyte subsets and inflammation-linked indices (NLR, LCR/LeCR) and posits potential metabolic benefits. However, mechanistic pathways (e.g., receptor-level signaling, cytokine networks) were not directly measured in this study.
Dosages and adverse reactions
AFO-202: 2 g/day (two 1-g sachets) and N-163 (when combined): 15 g gel/day (one sachet).
No adverse event data are reported.
Quality of study
Strengths: randomized allocation; clearly defined dose regimens and multi-domain biomarker panel; inclusion of both 21- and 35-day exposures.
Limitations: very small n (n=4/group), healthy male volunteers only, reliance on within-group pre/post changes, no significant 21 vs 35-day differences, and limited statistical detail for between-group effects; overall exploratory quality requiring confirmation.
Implications
In healthy middle-aged men, oral A. pullulans β-glucans may modulate glycemic, lipid, and inflammation-linked indices in pattern-specific ways (AFO-202 for glycaemia; AFO-202+N-163 for lipids/innate markers). These data are early findings and clinicians should avoid efficacy extrapolation to patients with metabolic disease until larger, controlled trials with safety reporting and mechanistic endpoints are available.
This summary is based on peer-reviewed scientific research. We use AI tools to help condense complex studies, but all content is reviewed and approved by qualified experts before publication.
Citation
Copied!